Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone

Dae Wook Kang, John K. DiBaise, Zehra Esra Ilhan, Michael D. Crowell, Jai Ram Rideout, James G Caporaso, Bruce E. Rittmann, Rosa Krajmalnik-Brown

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Identifying specific gut microorganisms associated with chronic constipation may be useful for diagnostic and therapeutic purposes. The objective of this study was to evaluate whether or not the gut microbial community of constipated subjects had specific microbial signatures and to assess the effects of lubiprostone treatment on the gut microbial community. Stool diaries, breath H2 and CH4 levels, and stool samples were collected from ten healthy subjects and nine patients meeting the Rome III criteria for chronic functional constipation. Constipated subjects received lubiprostone for four weeks, during which stool diaries were maintained. Stool samples were evaluated for gut microbial communities using pyrosequencing and quantitative real-time PCR (qPCR) targeting 16S-rRNA gene, along with concentrations of short-chain fatty acids (SCFAs) using high-performance liquid chromatography. Prior to treatment, gut microbial profiles were similar between constipated subjects and healthy subjects, while iso-butyrate levels were significantly higher in constipated subjects compared with healthy subjects. Despite increases in stool frequency and improvements in consistency after lubiprostone treatment, gut microbial profiles and community diversity after treatment showed no significant change compared to before treatment. While we did not observe a significant difference in either breath methane or archaeal abundance between the stool samples of healthy and constipated subjects, we confirmed a strong correlation between archaeal abundance measured by qPCR and the amount of methane gas exhaled in the fasting breath. Butyrate levels, however, were significantly higher in the stool samples of constipated subjects after lubiprostone treatment, suggesting that lubiprostone treatment had an effect on the net accumulation of SCFAs in the gut. In conclusion, lubiprostone treatment improved constipation symptoms and increased levels of butyrate without substantial modification of the gut microbial structure.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalAnaerobe
Volume33
DOIs
StatePublished - Jun 1 2015

Fingerprint

Volatile Fatty Acids
Constipation
Butyrates
Healthy Volunteers
Therapeutics
Methane
Lubiprostone
rRNA Genes
Real-Time Polymerase Chain Reaction
Fasting
Gases
High Pressure Liquid Chromatography

Keywords

  • Constipation
  • Gut microbiome
  • Lubiprostone
  • Pyrosequencing
  • Short-chain fatty acids

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases

Cite this

Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone. / Kang, Dae Wook; DiBaise, John K.; Ilhan, Zehra Esra; Crowell, Michael D.; Rideout, Jai Ram; Caporaso, James G; Rittmann, Bruce E.; Krajmalnik-Brown, Rosa.

In: Anaerobe, Vol. 33, 01.06.2015, p. 33-41.

Research output: Contribution to journalArticle

Kang, Dae Wook ; DiBaise, John K. ; Ilhan, Zehra Esra ; Crowell, Michael D. ; Rideout, Jai Ram ; Caporaso, James G ; Rittmann, Bruce E. ; Krajmalnik-Brown, Rosa. / Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone. In: Anaerobe. 2015 ; Vol. 33. pp. 33-41.
@article{776c9c8732e44efaa71ef7f05ad0eb6a,
title = "Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone",
abstract = "Identifying specific gut microorganisms associated with chronic constipation may be useful for diagnostic and therapeutic purposes. The objective of this study was to evaluate whether or not the gut microbial community of constipated subjects had specific microbial signatures and to assess the effects of lubiprostone treatment on the gut microbial community. Stool diaries, breath H2 and CH4 levels, and stool samples were collected from ten healthy subjects and nine patients meeting the Rome III criteria for chronic functional constipation. Constipated subjects received lubiprostone for four weeks, during which stool diaries were maintained. Stool samples were evaluated for gut microbial communities using pyrosequencing and quantitative real-time PCR (qPCR) targeting 16S-rRNA gene, along with concentrations of short-chain fatty acids (SCFAs) using high-performance liquid chromatography. Prior to treatment, gut microbial profiles were similar between constipated subjects and healthy subjects, while iso-butyrate levels were significantly higher in constipated subjects compared with healthy subjects. Despite increases in stool frequency and improvements in consistency after lubiprostone treatment, gut microbial profiles and community diversity after treatment showed no significant change compared to before treatment. While we did not observe a significant difference in either breath methane or archaeal abundance between the stool samples of healthy and constipated subjects, we confirmed a strong correlation between archaeal abundance measured by qPCR and the amount of methane gas exhaled in the fasting breath. Butyrate levels, however, were significantly higher in the stool samples of constipated subjects after lubiprostone treatment, suggesting that lubiprostone treatment had an effect on the net accumulation of SCFAs in the gut. In conclusion, lubiprostone treatment improved constipation symptoms and increased levels of butyrate without substantial modification of the gut microbial structure.",
keywords = "Constipation, Gut microbiome, Lubiprostone, Pyrosequencing, Short-chain fatty acids",
author = "Kang, {Dae Wook} and DiBaise, {John K.} and Ilhan, {Zehra Esra} and Crowell, {Michael D.} and Rideout, {Jai Ram} and Caporaso, {James G} and Rittmann, {Bruce E.} and Rosa Krajmalnik-Brown",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.anaerobe.2015.01.005",
language = "English (US)",
volume = "33",
pages = "33--41",
journal = "Anaerobe",
issn = "1075-9964",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone

AU - Kang, Dae Wook

AU - DiBaise, John K.

AU - Ilhan, Zehra Esra

AU - Crowell, Michael D.

AU - Rideout, Jai Ram

AU - Caporaso, James G

AU - Rittmann, Bruce E.

AU - Krajmalnik-Brown, Rosa

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Identifying specific gut microorganisms associated with chronic constipation may be useful for diagnostic and therapeutic purposes. The objective of this study was to evaluate whether or not the gut microbial community of constipated subjects had specific microbial signatures and to assess the effects of lubiprostone treatment on the gut microbial community. Stool diaries, breath H2 and CH4 levels, and stool samples were collected from ten healthy subjects and nine patients meeting the Rome III criteria for chronic functional constipation. Constipated subjects received lubiprostone for four weeks, during which stool diaries were maintained. Stool samples were evaluated for gut microbial communities using pyrosequencing and quantitative real-time PCR (qPCR) targeting 16S-rRNA gene, along with concentrations of short-chain fatty acids (SCFAs) using high-performance liquid chromatography. Prior to treatment, gut microbial profiles were similar between constipated subjects and healthy subjects, while iso-butyrate levels were significantly higher in constipated subjects compared with healthy subjects. Despite increases in stool frequency and improvements in consistency after lubiprostone treatment, gut microbial profiles and community diversity after treatment showed no significant change compared to before treatment. While we did not observe a significant difference in either breath methane or archaeal abundance between the stool samples of healthy and constipated subjects, we confirmed a strong correlation between archaeal abundance measured by qPCR and the amount of methane gas exhaled in the fasting breath. Butyrate levels, however, were significantly higher in the stool samples of constipated subjects after lubiprostone treatment, suggesting that lubiprostone treatment had an effect on the net accumulation of SCFAs in the gut. In conclusion, lubiprostone treatment improved constipation symptoms and increased levels of butyrate without substantial modification of the gut microbial structure.

AB - Identifying specific gut microorganisms associated with chronic constipation may be useful for diagnostic and therapeutic purposes. The objective of this study was to evaluate whether or not the gut microbial community of constipated subjects had specific microbial signatures and to assess the effects of lubiprostone treatment on the gut microbial community. Stool diaries, breath H2 and CH4 levels, and stool samples were collected from ten healthy subjects and nine patients meeting the Rome III criteria for chronic functional constipation. Constipated subjects received lubiprostone for four weeks, during which stool diaries were maintained. Stool samples were evaluated for gut microbial communities using pyrosequencing and quantitative real-time PCR (qPCR) targeting 16S-rRNA gene, along with concentrations of short-chain fatty acids (SCFAs) using high-performance liquid chromatography. Prior to treatment, gut microbial profiles were similar between constipated subjects and healthy subjects, while iso-butyrate levels were significantly higher in constipated subjects compared with healthy subjects. Despite increases in stool frequency and improvements in consistency after lubiprostone treatment, gut microbial profiles and community diversity after treatment showed no significant change compared to before treatment. While we did not observe a significant difference in either breath methane or archaeal abundance between the stool samples of healthy and constipated subjects, we confirmed a strong correlation between archaeal abundance measured by qPCR and the amount of methane gas exhaled in the fasting breath. Butyrate levels, however, were significantly higher in the stool samples of constipated subjects after lubiprostone treatment, suggesting that lubiprostone treatment had an effect on the net accumulation of SCFAs in the gut. In conclusion, lubiprostone treatment improved constipation symptoms and increased levels of butyrate without substantial modification of the gut microbial structure.

KW - Constipation

KW - Gut microbiome

KW - Lubiprostone

KW - Pyrosequencing

KW - Short-chain fatty acids

UR - http://www.scopus.com/inward/record.url?scp=84922467857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922467857&partnerID=8YFLogxK

U2 - 10.1016/j.anaerobe.2015.01.005

DO - 10.1016/j.anaerobe.2015.01.005

M3 - Article

C2 - 25617726

AN - SCOPUS:84922467857

VL - 33

SP - 33

EP - 41

JO - Anaerobe

JF - Anaerobe

SN - 1075-9964

ER -